A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer

Summary

In this study, up to 21 patients with metastatic prostate cancer will receive UV1 (a therapeutic synthetic peptide vaccine) at different dose levels. The safety and tolerability of UV1 as well as immunological response will be assessed. The purpose of this study is to select a biological dose of peptides for further clinical trials. Main treatment period is completed and reported. Follow-up ongoing.

Timeline

Start

2013-04-15

Primary completion

2015-07-08

Completion

2020-10-23

Publications

• Lilleby W, Seierstad T, Inderberg EM, Hole KH. Impact of human telomerase reverse transcriptase peptide vaccine combined with androgen deprivation therapy and radiotherapy in de novo metastatic prostate cancer: Long-term clinical monitoring. Int J Cancer. 2023 May 15;152(10):2166-2173. doi: 10.1002/ijc.34448. Epub 2023 Feb 4.

Drugs

Indications